ClinicalTrials.gg
Enrolling by invitationNCT07947706Updated Nov 19, 2026

Chronic HBV Patients With Hepatic Steatosis : Clinical and Portal Doppler Outcomes.

A Phase 1/2 interventional study of Empagliflozin (EMPA) in Empagliflozin, Hepatitis B and Steatosis, sponsored by Assiut University. Enrolling by invitation at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Assiut University · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

In this study, the investigators aimed to evaluate the hepatoprotective effect of empagliflozin against HBV-induced liver injury by comparing patients demographic , laboratory date ( liver function , viremia ) , degree of hepatic steatosis and fibrosis and portal doppler at the beginning and after six months

Read the detailed description

Hepatitis B virus (HBV) is a hepatotropic virus and an important human pathogen. There are an estimated 296 million people in the world that are chronically infected by this virus, and many of them will develop severe liver diseases including hepatitis, cirrhosis and hepatocellular carcinoma (HCC).

Hepatic steatosis is present in about one-third of the Chronic HBV population , and approximately 40% have fibrosis (F2-F4). The concurrence of hepatic steatosis could impact the replication of HBV and the effectiveness of antiviral drugs .

Empagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor, is a novel oral hypoglycemic agent that inhibits glucose reabsorption. Recent small-scale randomized controlled trials have shown that empagliflozin also improved hepatic steatosis and beneficial effects of empagliflozin on histological components including fibrosis were suggested from an uncontrolled pilot trial. The underlying mechanisms remain largely unknown; however, apart from weight loss, they may even include improvement of adipose tissue function with amelioration of local inflammation and/or oxidative stress. The decrease in liver fat content is independent of the decrease in plasma glucose concentration and is strongly related to the decrease in body weight and improvement in insulin sensitivity.

Hence, this research aiming to investigate the effectiveness and security of empagliflozin in chronic HBV with Hepatic steatosis .

Study tools :

  • All patients will be included within certain inclusion criteria after informed consent from patients and permission from the hospital board to review patients' medical records.
  • Patients will be randomly divided into two groups , the first will receive empagliflozin at a dose of 10 mg once daily and antiviral drug ,and the other will receive the antiviral drug only for six months
  • All patients at the beginning of the study and at the end of six months will be subjected to:

    1. Full history taking:

  • Name.
  • Age.
  • Sex.
  • Duration of HBV infection and type of drugs 2. Anthropometric measures
  • Height in cm.
  • Weight in kg.
  • Body mass index (kg/m²) 3. Systemic examination Including cardiac, chest and abdominal examination will be done to detect associated or excluded conditions.

    4. Laboratory tests:

    • Complete blood picture.
    • Liver function test .
    • Coagulation profile .
    • hepatitis marker (HBs Ag , Anti-HCV Ab).
    • HBV DNA PCR . 5. Radiological:
    • Fibroscan:
  • The device consists of a vertically oriented mobile cuboid main body and one or several cylindrical probes. Liver stiffness measurements (LSMs) were performed after 3 hours of fasting in the right lobe of the liver through the intercostal spaces with the patient in the supine position with their right rib cage spread (which is accomplished by elevating the right hand and/or crossing the right leg over the left). After gel application, the probe is positioned perpendicular to the skin surface in one of the intercostal spaces adjacent to the right lobe of the liver (typically the 9thto 11thintercostal space, on the midaxillary line). After adequate positioning, a low frequency shear wave is induced by a small piston positioned on the tip of the probe that hits the skin surface.
  • The acquired data are processed and displayed on the screen as LSM which estimate the stage of fibrosis and controlled attenuation parameter (CAP) which assess amount of steatosis.
  • The examiner takes repeated measurements with the following criteria for validation:

    1. At least 10 valid measurements.
    2. Ratio of number of valid measurements to the total number of measurements is ≥ 60%.
    3. Interquartile range (IQR), which reflects the variability of measurements, is less than 30% of the median value of liver stiffness measurements .The entire exam takes approximately 5 minutes .
  • CAP values range from 100 to 400 dB/m, and higher numbers indicate more pronounced steatosis. The advantage of CAP is that it is simultaneously calculated with the LSM and from the same region of interest .

CAP Score Steatosis grade Portion of liver affected by fatty change 238 to 260 dB/m S1 Less than ⅓ (11% to 33%) 260 to 290 dB/m S2 Between ⅓ and ⅔ (34% to 66%) 290 to 400 dB/m S3 More than ⅔ (67%)

- Hepatic fibrosis : LSM values range from 1.5 to 75 kPa; lower values indicate a more elastic liver. The more the liver stiffness, the more the fibrosis. The results are affected by the amount of pressure applied to the probe. The resulting LSM is translated into an estimate of the level of liver fibrosis in a simple and straightforward manner .

Liver Stiffness Result Fibrosis Score the Liver 2 to 7 kPa F0 to F1 Is normal. 8 to 9 kPa F2 Has moderate scarring. 8 to 11 kPa F3 Has severe scarring. 12 kPa or higher F4 Has cirrhosis.

  • Abdominal ultrasound : to assess the liver (echogenicity, surface, edge, and size), attenuation of hepatic veins, spleen size, and presence of ascites.
  • Doppler ultrasound: to measure the portal vein diameter (PVD), portal vein velocity (PVV), portal vein blood flow (PVBF), portal vein flow direction, hepatic artery resistance index and hepatic artery pulsatility index (HARI and HAPI, respectively), splenic artery resistance index (SARI), portal hypertension index (PHI), and modified liver vascular index and liver vascular index (MLVI and LVI, respectively).

Doppler analysis will be performed during quiet respiration or while the patients hold their breath . All parameters will be measured twice, at the beginning and at the end of the study. The examiner placed the Doppler gate in the hilum of the spleen and in the porta hepatis of the liver. The same observer usually will unify the method for measuring each index to avoid inter observer variability and calculate the mean of 3 consecutive measurements.

PVD : is measured from the hilar segment when crossing the inferior vena cava while the patient is in the recumbent supine position. It is recorded in millimeters.

PVBF: is calculated automatically after recording the peak, lowest, and mean venous velocity of the flow and the measurement of a cross-sectional area of the vessel lumen in a transverse plane. It is recorded in liters per minute (L/min). Portal vein flow direction: the direction of portal blood flow is shown by color Doppler, indicating if it is toward (hepatopetal) or away from the liver (hepatofugal).

PVV: is calculated automatically after measuring (Vmax) and (Vmin). It is recorded in centimeters per second (cm/sec).

HARI: The hepatic artery is evaluated by demonstrating the artery proper while crossing the portal vein. HARI is calculated automatically after measuring the hepatic artery peak velocity and end diastolic velocity measured in meters per second (m/sec) at the porta hepatis. The resistance index is calculated using the following equation: [peak systolic velocity (V max) - end diastolic velocity/peak systolic velocity (V min)/mean velocity] .

HAPI : is calculated automatically using the following equation: [(V max) - (V min)/mean velocity] .

The resistance index and wave form of the right hepatic vein: is measured as the maximum negative velocity - minimum negative velocity (or positive velocity in case of triphasic flow signal)/maximum negative velocity.

Hepatic vein waveforms : is described as triphasic, biphasic, monophasic, or not assessed because of severe attenuation.

SARI: Color Doppler allow identification of the main branches of the splenic artery by placing the transducer below the left costal margin . SARI is measured automatically after measuring (Vmax) and (Vmin), which is measured in meters per second (m/sec) by putting the cursor in the main branches of the splenic artery at the splenic hilum at the left intercostal space .

The resistance index : is calculated using the following equation: [(Vmax) - (Vmin)]/peak systolic velocity] .

PHI : is calculated as (HARI × 0.69) × (SARI × 0.87)/PVV . It is recorded in m/sec.

LVI : is calculated as PVV/HAPI . It is recorded in cm/sec. MLVI : is calculated as PVV/HARI . It is recorded in cm/sec.

5-Data management and analysis: Data collection: patients' clinical history, physical examination, laboratory results and imaging studies.

Computer software: SPSS(Statistical Package for the Social Science) version 20. Statistical tests: Data will be statistically described in terms of mean, standard deviation (SD), or frequencies (number of cases) and percentages when appropriate . A comparison of quantitative variables between the study groups will be done using Student t-test for independent samples. For comparing categorical data, Chi-square (χ2) test was performed. P values of less than 0.05 were considered statistically significant.

02

Conditions studied

  • Empagliflozin
  • Hepatitis B
  • Steatosis
03

In context

Hepatitis B

1,048 studies on the registry are indexed under Hepatitis B; 140 are open to participants now.

This study's planned enrollment of 84 is below the median of 145 across 757 interventional studies indexed under Hepatitis B.

Browse Hepatitis B studies →

Lead sponsor

Assiut University is the lead sponsor of 5,094 studies on the registry; 2,188 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18 years of age or older who had diagnosed as chronic on treatment with with Controlled Attenuation Parameter (CAP) value more than 238 dB/m .

Exclusion criteria

Exclusion Criteria:

  • patients under the age of 18.
  • patients with other viral hepatitis infection .
  • Hepatocellular carcinoma .
  • portal vein thrombosis.
  • Subjects with risk of 2nd hepatic steatosis liver disease (excessive alcohol consumption and medications).
  • history of liver disease such as (α-1 antitrypsin deficiency, hepatitis, drug-induced liver injury, 1ry biliary cirrhosis, 1ry sclerosing cholangitis).
  • (BMI) > 35 (to avoid the possibility of Fibroscan failure).
  • Patient with end organ disease.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    the group will receive empagliflozin

    The first group that will receive empagliflozin for six months

    Drug: Empagliflozin (EMPA)

  • No intervention
    the group will not receive empagliflozin.

    Control group

Interventions

  • DrugEmpagliflozin (EMPA)

    Empagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor, is a novel oral hypoglycemic agent that inhibits glucose reabsorption.

06

What researchers measure

Primary outcomes

  1. Degree of hepatic steatosis before and after six months of empagliflozin use

    comparing result of fibroscan regarding degree of steatosis ,controlled attenuation parameter (CAP) which assess amount of steatosis, before and after six months of using empagliflozin

    Time frame: 6 months

Secondary outcomes

  1. portal vein doppler assessment

    assessment of portal vein doppler before and after six months of empagliflozin for evaluating : Portal vein flow direction and portal vein diameter : the direction of portal blood flow is shown by color Doppler, indicating if it is toward (hepatopetal) or away from the liver (hepatofugal). and the diameter is measured from the hilar segment when crossing the inferior vena cava while the patient is in the recumbent supine position. It is recorded in millimeters normal value \<13 mm diameter.

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Publications

  • Abdelgani S, Khattab A, Adams J, Baskoy G, Brown M, Clarke G, Larvenenko O, DeFronzo RA, Abdul-Ghani M. Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes. Diabetes Care. 2024 Apr 1;47(4):668-675. doi: 10.2337/dc23-1646. PubMed 38295394 ↗
  • Tsai KF, Chen YL, Chiou TT, Chu TH, Li LC, Ng HY, Lee WC, Lee CT. Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases. Antioxidants (Basel). 2021 Jul 22;10(8):1166. doi: 10.3390/antiox10081166. PubMed 34439414 ↗
  • Dewidar B, Kahl S, Pafili K, Roden M. Metabolic liver disease in diabetes - From mechanisms to clinical trials. Metabolism. 2020 Oct;111S:154299. doi: 10.1016/j.metabol.2020.154299. Epub 2020 Jun 20. PubMed 32569680 ↗
  • Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013 Oct;1(2):140-51. doi: 10.1016/S2213-8587(13)70050-0. Epub 2013 Aug 13. PubMed 24622320 ↗
  • Jiang D, Chen C, Liu X, Huang C, Yan D, Zhang X, Zhou Y, Lin Y, Zhou Y, Guan Z, Ding C, Lan L, Zhu C, Wu J, Li L, Yang S. Concurrence and impact of hepatic steatosis on chronic hepatitis B patients: a systematic review and meta-analysis. Ann Transl Med. 2021 Dec;9(23):1718. doi: 10.21037/atm-21-3052. PubMed 35071412 ↗
  • Zheng Q, Zou B, Wu Y, Yeo Y, Wu H, Stave CD, Cheung RC, Nguyen MH. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Aliment Pharmacol Ther. 2021 Nov;54(9):1100-1109. doi: 10.1111/apt.16595. Epub 2021 Sep 1. PubMed 34469587 ↗
  • GBD 2019 Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022 Sep;7(9):796-829. doi: 10.1016/S2468-1253(22)00124-8. Epub 2022 Jun 21. PubMed 35738290 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Apr 2027, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2026
First posted
Nov 19, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
May 1, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947706
Lead sponsor
Assiut University
Responsible party
Michael Melad Fekry Endrawes (Assistant lecturer of internal medicine, Assiut University) — Principal investigator
First posted
Nov 19, 2026
Start date
Sep 1, 2026
Primary completion
Apr 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Nov 19, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion